Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07254572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07254572
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07254572. Randomized; no masking; primary purpose treatment. Start 2025-07-10 (actual); primary completion 2029-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
Acronym
CASCADES
Condition
PreDiabetes
Intervention (Drug)
Semaglutide 14 MG [Rybelsus]
Intervention (Drug)
Dapagliflozin (Forxiga)
Intervention (Drug)
Metformin
Intervention (Behavioral)
Optimal Medical Therapy (OMT) And Lifestyle Intervention
Lead sponsor
National Institute of Cardiology, Warsaw, Poland (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)

Record details

Record id
cardio:ct-nct07254572
Content hash
e905a60716608b8369a8a3b5883bc6c6e920eb5f129958ee279150ac543cda30